Doxycycline Monohydrate 25 mg (5mL) Oral Suspension Under Fed Conditions

NCT00829790 | Completed Phase 1 Results

• 1 other identifier: 20-065-SA
• Study Type: interventional
• Target: 30
• Locations: 1 country
• Sites: 1

Brief Summary

The objective of this study was to compare the rate of absorption and the oral bioavailability of a test formulation of doxycycline monohydrate 1 x 25 mg (5mL) oral suspension manufactured by IVAX Pharmaceuticals, Inc. and distributed by TEVA Pharmaceuticals USA to an equivalent oral dose of the commercially available reference product, Vibramycin Monohydrate® manufactured by Pfizer, Inc. Following an overnight fast of at least 10 hours, subjects consumed a standard high-calorie. high-fat breakfast meal. This standard breakfast meal began 30 minutes prior to each dose.

Conditions

Healthy

Keywords

Bioequivalence; Healthy Subjects

Outcome Measures

Primary Outcomes (3)

• Cmax = Maximum Observed Concentration.

  Bioequivalence based on Cmax.

  Blood samples collected over a 72 hour period.

• AUC0-t = Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration.

  Bioequivalence based on AUC0-t.

  Blood samples collected over a 72 hour period.

• AUC0-inf = Area Under the Concentration-time Curve From Time Zero to Infinity.

  Bioequivalence based on AUC0-inf.

  Blood samples collected over a 72 hour period.

Study Arms (2)

1

EXPERIMENTAL

Doxycycline Monohydrate

Drug: Doxycycline Monohydrate

2

ACTIVE COMPARATOR

Vibramycin Monohydrate®

Drug: Doxycycline Monohydrate

Interventions

Doxycycline Monohydrate DRUG

25 mg 5mL oral dose

1

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• All subjects must satisfy the following criteria to be considered for study participation:
• Subject must be male or non-pregnant, non-breast-feeding female
• Subject must be at least 18 years of age
• Subject must have a Body Mass Index (BMI) between 18 and 30 kg/m2, inclusive, and body weight should be at least 50 kg (110 lbs)
• Female Subjects - not surgically sterile or at least two years postmenopausal - must agree to utilize one of the following forms of contraception, if sexually active with a male partner, from screening through completion of the study. Approved forms of contraception are abstinence, double barrier (condom with spermicide, diaphragm with spermicide), intra-uterine device (IUD), or vasectomized partner (6 months minimum since vasectomy).
• Subject must voluntarily consent to participate in this study and provide their written informed consent prior to the start of any study-specific procedures.
• Subject is willing and able to consume the entire high-calorie, high-fat breakfast meal in the designated timeframe required during each study period.
• Subject is willing and able to remain in the study unit for the entire duration of each confinement period and return for any outpatient visits.

You may not qualify if:

• Subjects may be excluded for any of the following:
• History or presence of clinically significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, oncologic, or psychiatric disease or any other condition which, in the opinion of the Investigator would jeopardize the safety of the subject or the validity of the study results.
• Has a clinically significant abnormal finding on the physical exam, medical history, ECG or clinical laboratory results at screening.
• History or presence of allergic or adverse response to doxycycline monohydrate or related drugs.
• Has been on a significantly abnormal diet during the four weeks preceding the first dose of study medication.
• Has donated blood or plasma within 30 days prior to the first dose of study medication.
• Has participated in another clinical trial within 30 days prior to the first dose of study medication.
• Has used any over-the-counter (OTC) medication, including nutritional supplements, within 7 days prior to the first dose of study medication.
• Has used any prescription medication, including hormonal contraceptive or hormonal replacement therapy, within 14 days prior to the first dose of study medication.
• Has been treated with any known enzyme altering drugs such as barbiturates, phenothiazines, cimetidine, carbamazepine, etc., within 30 days prior to the first dose of study medication.
• Has smoked or used tobacco products within 90 days prior to the first dose of study medication.
• Is a female with a positive pregnancy test result.
• Has an intolerance to venipuncture.
• Has a positive urine screen for drugs of abuse (amphetamines, barbiturates, benzodiazepines, cocaine, cannabinoids, opiates)
• Has a history of drug or alcohol abuse.

Sponsors & Collaborators

• Teva Pharmaceuticals USA: lead

Study Sites (1)

CEDRA Clinical Research

San Antonio, Texas, 78217, United States

Location

MeSH Terms

Interventions

Doxycycline

Intervention Hierarchy (Ancestors)

Tetracyclines; Naphthacenes; Polycyclic Aromatic Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydrocarbons; Organic Chemicals; Polycyclic Compounds

Results Point of Contact

• Title: Manager, Biopharmaceutics
• Organization: TEVA Pharmaceuticals USA

clinicaltrialqueries@tevausa.com

1-866-384-5525

Study Officials

• Frederick A Bieberdorf, M.D.

  CEDRA Clinical Research

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: OTHER
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY

Study Record Dates

• First Submitted: January 26, 2009
• First Posted: January 27, 2009
• Study Start: October 1, 2006
• Primary Completion: October 1, 2006
• Study Completion: October 1, 2006
• Last Updated: August 19, 2024
• Results First Posted: August 4, 2009

Record last verified: 2024-08

Locations

US (1)